- Home
- INZY vs HBIO Comparison
INZY vs HBIO Comparison
Compare INZY & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- HBIO
- Stock Information
- Founded
- INZY 2015
- HBIO 1901
- Country
- INZY United States
- HBIO United States
- Employees
- INZY N/A
- HBIO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- INZY Health Care
- HBIO Industrials
- Exchange
- INZY Nasdaq
- HBIO Nasdaq
- Market Cap
- INZY 64.9M
- HBIO 61.2M
- IPO Year
- INZY 2020
- HBIO 2000
- Fundamental
- Price
- INZY $0.91
- HBIO $0.57
- Analyst Decision
- INZY Strong Buy
- HBIO Buy
- Analyst Count
- INZY 10
- HBIO 1
- Target Price
- INZY $16.90
- HBIO $4.50
- AVG Volume (30 Days)
- INZY 517.6K
- HBIO 377.6K
- Earning Date
- INZY 03-10-2025
- HBIO 03-12-2025
- Dividend Yield
- INZY N/A
- HBIO N/A
- EPS Growth
- INZY N/A
- HBIO N/A
- EPS
- INZY N/A
- HBIO N/A
- Revenue
- INZY N/A
- HBIO $94,135,000.00
- Revenue This Year
- INZY N/A
- HBIO N/A
- Revenue Next Year
- INZY N/A
- HBIO $7.97
- P/E Ratio
- INZY N/A
- HBIO N/A
- Revenue Growth
- INZY N/A
- HBIO N/A
- 52 Week Low
- INZY $0.88
- HBIO $0.56
- 52 Week High
- INZY $7.80
- HBIO $4.70
- Technical
- Relative Strength Index (RSI)
- INZY 32.10
- HBIO 22.38
- Support Level
- INZY $0.94
- HBIO $0.56
- Resistance Level
- INZY $1.03
- HBIO $0.63
- Average True Range (ATR)
- INZY 0.08
- HBIO 0.06
- MACD
- INZY 0.01
- HBIO 0.02
- Stochastic Oscillator
- INZY 13.64
- HBIO 3.00
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.